Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
Understanding Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)January 17th 2023
Lori Wirth, MD, provides an overview of radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC), the standard-of-care treatment options, and the importance of testing for molecular alterations in patients with RAI-R-DTC.
Metastatic Renal Cell Carcinoma: Updates to CheckMate 9ER and COSMIC-313 Trial DataDecember 20th 2022
Rana McKay, MD discusses emerging data in the metastatic renal cell carcinoma treatment landscape, reviewing the current standard of care and then delving into recent data updates from the CheckMate 9ER and COSMIC-313 trials.
Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with LenvatinibNovember 16th 2022
Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.
Potential Role of Elacestrant for the Treatment of Metastatic ER+/HER2- Breast CancerOctober 31st 2022
Dr Aditya Bardia reviews the potential role of elacestrant for the treatment of metastatic ER+/HER2- breast cancer, starting with an overview of the current landscape and focusing specifically on key efficacy data from the EMERALD Trial.
Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial DataApril 14th 2022
Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.
The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaDecember 1st 2021
Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.
Transarterial Yttrium-90 Radioembolization with Chemotherapy for the Treatment of Colorectal Liver Metastasis: The EPOCH StudyNovember 1st 2021
Mary F. Mulcahy, MD, breaks down the phase III EPOCH study and explains how it has affected the treatment of colorectal cancer with liver metastasis.
Transplant Ineligible Multiple Myeloma: Updates to the MAIA StudySeptember 30th 2021
Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.
AMEERA-1: Phase 1-2 Study of Amcenestrant, An Oral Selective Estrogen Receptor Degrader, With Palbociclib in Postmenopausal Women With ER+ HER2- Metastatic Breast CancerSeptember 9th 2021
Sarat Chandarlapaty, MD, discusses the treatment landscape of metastatic ER+/HER2- breast cancer, including observations made from the results of the AMEERA-1 trial and the use of amcenestrant as a therapy option.
Ruxolitinib for Steroid-Refractory GVHD: The REACH TrialsJuly 21st 2021
In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.
Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular CarcinomaJuly 20th 2021
An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.